Introduction
============

In the past decade the field of gastrointestinal (GI)-related diseases has received ample interest. Physicians treating GI disorders had to face new challenges during recent years. On the one hand GI-related problems are growing rapidly within the population, especially in older patients and those with the following disorders: diarrhea, irritable bowel disease, pouchitis, Crohn's disease or ulcerative pouchitis; on the other hand; efficient and safe treatment has yet to arrive. By increasing the cost of medical care there has been an obvious need for a more reliable treatment method of higher efficacy. GI research is constantly working on exploring new techniques, designing new systems, and discovering new ways of delivering certain drugs of interest to the target organs. In particular, GI cancers pose major public health problems in the United States as well as most western countries. There are six main diseases associated with colon: Crohn's disease (ileitis or enteritis), diverticulitis, ulcerative colitis, irritable bowel syndrome (IBS), colonic dismotility, and colon cancer.

A significant health care burden is associated with IBS, with increased out-patient services, abdominal and pelvic surgeries, and GI- and non-GI-related physician visits and health care costs. Functional GI disorders such as functional dyspepsia, IBS, and other chronic medical conditions like gastroesophageal reflux disease and asthma impact significantly the patient's health-related quality of life. Impaired health-related quality of life has been demonstrated, in particular, in patients with moderate to severe disease seen in referral settings. Although the quality of life appears to improve in treatment responders, or correlates with symptom improvement, with at least some treatment modalities studied in functional gastrointestinal disorders it still required further studies. The significance of psychological factors such as early adverse life events or symptoms related to visceral perception such as pain and chronic stress further contribute to impairment of health-related quality of life in patients with functional GI disorders. The presence of extraintestinal symptoms appears to have a major if not greater impact on health care visits, excess health care costs, and health-related quality of life in patients with functional GI disorders ([@b28-btt-2-355]).

This review covers state of the art methods and technologies for targeted GI delivery of oral live cells, with in depth coverage of live cell biotherapeutics used in treatment of various GI disorders. In addition, the potential and limitations as well as future perspectives are discussed.

Colon, an ideal place for action of biotherapeutics molecules -- overview of GI tract and its molecular basis
=============================================================================================================

Esophagus, stomach, duodenum, small intestine (ileum), large intestine (colon), appendix, liver, gallbladder and pancreas all comprise a gut by forming a tube connection between mouth and anus through which food passes. GI tract (GIT) is a tubular passage made of muscle and mucous membrane that extends about 8.3 meters in length. Colon, a tube-like organ is made of 4 sections: the ascending colon, transverse colon, the descending colon, the sigmoid colon and it is about 1.5 to 2 meters long. Its primary function is to absorb water and salts from undigested foods and store the waste-products until excreted. The colon is viewed as the preferred absorption site for oral administration of protein and peptide drugs because of the relatively low proteolytic enzyme activities in the colon ([@b234-btt-2-355]).

The flora of the GIT in mammals is highly complex and diverse. The normal intestinal immune system is under a balance in which proinflammatory and antiinflammatory cells and molecules are carefully regulated to promote a normal host mucosal defense capability without destruction of intestinal tissue ([@b80-btt-2-355]). Once this careful regulatory balance is disturbed, nonspecific stimulation and activation can lead to increased amounts of potent destructive immunological and inflammatory molecules being produced and released. The concept of balance and regulation of normal mucosal immune and inflammatory events is indicative of how close the intestine is to developing severe inflammation. The normal intestinal mucosal immune system is constantly stimulated by lumenal contents and bacteria ([@b128-btt-2-355]). 95% of bacteria residing in GIT are obligate anaerobes with species like: *Bifidobacterium*, *Clostridium*, *Eubacterium*, *Fusobacterium*, *Peptococcus*, *Peptostreptococcus*, and *Bacteroides* and 10% is made of facultative anaerobes: *Lactobacillus*, *Escherichia coli*, *Klebsiella*, *Streptococcus*, *Staphylococcus*, and *Bacillus.* It has been estimated that there are approximately 10^12^ viable bacteria per gram of large bowel content in humans, with the presence of at least 400 to 500 species ([@b196-btt-2-355]; [@b12-btt-2-355]). The stimulatory molecules present in the intestinal lumen that activate and induce subsequent mucosal immunologic and inflammatory events include bacterial cell wall products, such as peptidoglycans and lipopolysaccharides, as well as other chemotactic and toxic bacterial products that are produced by the many different types of bacteria within the GIT ([@b128-btt-2-355]).

The complex intestinal human defense system consists of innate and adaptive immune systems, which further are composed of intraluminal breakdown like gastric acid, pancreatic enzymes and bile as well as prevention of adhesion like intestinal motility and mucus layer. The intestinal motility, when disturbed, may promote bacterial overgrowth. The layer of mucus holds an important nonimmune gut barrier role. It forms two compartments: viscoelastic gel and superficial hydrosoluble layer which are composed of water, mucin glycoproteins and lipids. Mucus can also act as an antioxidant and counteract inflammatory mediators and byproducts ([@b143-btt-2-355]; [@b120-btt-2-355]). Its main functions include physical and epithelial barrier with intercellular tight junctions and constant cell turnover, a site for glycoproteins to compete with gut surface for bacterial or antigen binding as well as a site which favors bacterial colonization.

The mucous layer and mucin production are qualitatively and quantitatively altered in many situations of intestinal stress, including the inflammatory bowel diseases (IBD) ([@b143-btt-2-355]), ulcerative colitis (UC), and Crohn's disease ([@b41-btt-2-355]). For example, in the active phase of the disease, UC patients exhibit reductions in the thickness of the colonic mucous layer, in the number of mucus-containing goblet cells, and in ex vivo analyzed MUC2 production (the main secreted-colonic mucin) ([@b62-btt-2-355]). The intricate system of digestive tract to restrict its potentially harmful contents is further made of the epithelial layer with presence of intercellular tight junctions as well as expression of adherence factors on the surface ([@b221-btt-2-355]). The tight junctions provide protection of the intercellular spaces and restrict the passage via the extra cellular pathway. Any perturbation of the intestinal barrier may lead to promotion of bacterial adherence. For instance, a study revealed a redistribution of the tight junctional transmembrane protein upon infection with *Campylobacter jejuni* which is a leading cause of human enterocolitis and is associated with postinfectious complications, including IBS and Guillain-Barre syndrome ([@b127-btt-2-355]; [@b36-btt-2-355]). The adherence factors are expressed on the surface of epithelial cells. For instance, *Helicobacter pylori* has been identified as such agent which once attached to the epithelial surface initiates infection. Although a number of specific adhesins has been identified, other *H. pylori* virulence factors may play a role in adherence to gastric epithelial cells directly or through interaction with other adhesions ([@b240-btt-2-355]). The presence of adherence factors is genetically determined but the expression can be modified ([@b84-btt-2-355]). Pattern recognition receptors (PRRs) play a role in allowing innate immune cells to distinguish between "self" and microbial "nonself" based on the recognition of broadly conserved pathogen-associated molecular patterns (PAMPs) ([@b97-btt-2-355]). Toll-like receptors (TLRs) comprise a class of transmembrane PRRs which play a role in microbial recognition, induction of antimicrobial genes, and the control of adaptive immune responses ([@b228-btt-2-355]).

[Figure 1](#f1-btt-2-355){ref-type="fig"} summarizes briefly the concept of TLRs. TLRs are expressed in epithelial cells of the skin, respiratory, intestinal, and genitourinary tracts that form the first protective barrier to invading pathogens ([@b183-btt-2-355]). TLRs activate downstream effectors through adaptors that contain Toll/interleukin-1 receptor (TIR) domains, but the mechanisms accounting for diversification of TLR effector functions are unclear ([@b79-btt-2-355]). The adaptive immune system is composed of gut-associated lymphoid tissue (GALT) and epithelial cells. The cell-mediated branch of the adaptive immune response relies on mucosal T lymphocytes and the humoral defense is composed of B lymphocytes and plasma cells secreting IgA molecules. The lymphocytes are located in organized structures like Peyer's patches and isolated lymphoid follicles. The follicle-associated epithelium (FEA) spans the lymphoid structures of Peyer's patch and consists of cubical enterocytes (FEA cells) and M cells. M-cells are responsible for sampling of particulate microbial material ([@b82-btt-2-355]). It has been found that M cells get damaged and increased in inflamed human ileal mucosa ([@b45-btt-2-355]). More detailed description of molecular composition of GIT is beyond the scope of this review.

Due to high complexity of the microbiota and the limitation of widely used culture-based techniques, the dynamic changes in the composition of the normal GIT microbial species in immunocompetent hosts during aging, between genders, and after experimental infection with microbial pathogens are still not well understood ([@b70-btt-2-355]).

Colon-specific drug delivery -- methods and limitations
=======================================================

The old school colonic drug delivery approaches included four methods, namely, prodrugs, pH- and time-dependent systems, and microflora-activated systems. The continuous effort to establish new improved techniques of drug delivery yielded methods like pressure-controlled colon delivery capsules (PCDCs), CODES, colonic drug delivery system based on pectin and galactomannan coating, and Azo hydrogels. These approaches bear features like improved *in vivo* site specificity, versatile drug release kinetics, feasibility of the manufacturing process and design rationale to accommodate different therapeutic needs. These have been extensively described by [@b234-btt-2-355]. Other methods include: pro-drugs, timed-released systems, coating of pH-dependant polymer and the use of polysaccharides.

Novel approaches in colon-specific delivery system have been proposed like: a microbially triggered colon-targeted osmotic pump (MTCT-OP) ([@b123-btt-2-355]), TARGIT technology with application of pH-sensitive coatings onto injection-moulded starch capsules ([@b225-btt-2-355]), cross-linked microspheres of guar gum studied by [@b39-btt-2-355] in delivery of metronidazole and nanoparticles which are claimed to be able to deliver drugs to the inflammation site in severe cases of IBD where state-of-the-art delivery devices fail ([@b110-btt-2-355]).

Various GI diseases and their treatment limitations
===================================================

Collagenous colitis
-------------------

Collagenous colitis (CC) is primarily a disorder of middle-aged women and is characterized on biopsy by increased subepithelial collagen as well as increased inflammatory cells in the lamina propria and increased intraepithelial lymphocytes. Approximately 10% of lymphocytic colitis patients have a positive family history of some type of inflammatory intestinal disease, including UC, Crohn's disease, CC, and celiac disease. Lymphocytic colotis is a subtype of collagenous colitis and it is characterized by chronic nonbloody watery diarrhea. Therapy in lymphocytic colitis is less well studied, but the same medications are used with success, including budesonide and high dose bismuth subsalicylate ([@b116-btt-2-355]). Other drugs used include prednisolone and Boswellia serrata extract. A study by [@b57-btt-2-355] clearly implied that the treatment of patient with prednisolone may cause the collagenous colitis.

Diarrhea
--------

Drug-induced diarrhea is a relatively frequent adverse event, accounting for about 7% of all adverse effects of drug therapy, being more frequent in the elderly because of factors related to the aging process itself and the higher frequency of drug therapy ([@b31-btt-2-355]). More than 700 drugs have been implicated in causing diarrhea, which can appear a long time after the start of drug treatment, sometimes up to several months or years, and the diagnosis can be unrecognized ([@b199-btt-2-355]). In the case-control study by [@b63-btt-2-355] patients consumed a variety of drugs such as prednisone, diuretics, omeprazole, low-dose aspirin, bisphosphonates, and many more. The results revealed that the usage of selective serotonin reuptake inhibitors (SSRIs) and statins significantly related to the risk of chronic diarrhea ([@b63-btt-2-355]).

Microscopic colitis
-------------------

Microscopic colitis is a term used to define those entities characterized by chronic watery diarrhea, normal radiological and endoscopic appearance, and microscopic abnormalities in the colon. The entity includes CC and lymphocytic colitis (LC) ([@b27-btt-2-355]). Various studies include the following treatments: bismuth subsalicylates, budesonide, prednisolone, Boswellia serata, cholestyramine, and 5-aminosalicylic acid agents ([@b1-btt-2-355]). Insofar, the treatment with budesonide looks promising, however, the evidence for benefit with bismuth subsalicylate is weaker. Moreover, the effectiveness of prednisolone, Boswellia serrata extract and other therapies for induction or maintenance of remission of colitis is unknown and requires further study ([@b26-btt-2-355]).

Gastritis caused by *Helicobacter pylori*
-----------------------------------------

*Helicobacter pylori* is a Gram-negative, spiral bacterium that colonizes the gastric mucosa of at least 50% of the world's population and plays a causative role in the development of chronic gastritis as well as in gastric and duodenal ulcers ([@b218-btt-2-355]). This infection also represents a high risk factor in mucosa-associated lymphoid tissue lymphomas and gastric adenocarcinomas ([@b13-btt-2-355]; [@b46-btt-2-355]). Treatment regiments to eliminate gastric *H. pylori* infection are based on the association of two antibiotics and an antisecretory agent, most often a proton pump inhibitor. In a single-center randomized study the effect of high-dose intravenous proton pump inhibitor (omeprazole) alone (group 1) with omeprazole in combination with a low-dose prostaglandin analog (misoprostol; group 2) on clinical outcomes in patients with aspirin/ nonsteroidal antiinflammatory drug (NSAID)-induced upper GI bleeding was compared ([@b236-btt-2-355]). This trial concluded that adding misoprostol (600 μg/day) to standardized proton pump inhibitor treatment did not improve or change the rebleeding or mortality rates of patients with upper GI bleeding related to aspirin/NSAID use. In another study, patients with a history of upper GI bleeding who were infected with *H. pylori* and who were taking low-dose aspirin or other NSAIDs were screened ([@b25-btt-2-355]). It was found that among patients with *H. pylori* infection and a history of upper GI bleeding who were taking low-dose aspirin, the eradication of *H. pylori* was equivalent to treatment with omeprazole in preventing recurrent bleeding. Omeprazole turned out to be superior to the eradication of *H. pylori* in preventing recurrent bleeding in patients who are taking other NSAIDs. [@b204-btt-2-355] studied the efficacy of antibacterial therapy without medication to suppress gastric acid for the treatment of patients with *H. pylori* infection and gastric ulcers unrelated to the use of nonsteroidal agents. Patients received one-week course of antibacterial agents (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, each given orally four times a day) or a four-week course of omeprazole (20 mg orally per day). As a result, in patients with *H. pylori* infection and gastric ulcers unrelated to the use of NSAIDs, one week of antibacterial therapy without acid suppression heals the ulcers as well as omeprazole and reduces the rate of their recurrence.

Despite the success rates of various antibiotic combinations between 50%--75%, the antibiotic resistance and poor compliance significantly affect the effectiveness of these strategies. Furthermore, antibiotic-based therapies are not suited for large-scale eradication in populations like middle age individuals in emergent societies whose life expectancy changes, with a concomitant increased gastric cancer risk ([@b141-btt-2-355]).

Inflammatory bowel diseases
---------------------------

Today, the IBD, which include Crohn's disease and UC, affects 1 million people in the United States alone ([@b135-btt-2-355]). In the thorough study by [@b159-btt-2-355] the following common drugs in treatment of IBDs, UC, and Crohn's disease were analyzed: sulfasalazine and mesalazine, azathioprine (AZA) and 6-mercaptopurine (6-MP), methotrexate (MTX), glucocorticosteroids, and infliximab.

Various case reports suggest a relation between side effects like leukopenia and a mononucleosis-like syndrome and one of the slow acetylating genotypes in IBD patients treated with sulphasalazine ([@b150-btt-2-355]; [@b208-btt-2-355]). Side effects are less common with mesalazine compared to sulphasalazine but there is still some concern about nephrotoxicity with long term use ([@b159-btt-2-355]). The antiinflammatory effect of MTX therapy on IBD is not clearly known and no studies are available at this time ([@b159-btt-2-355]). Although glucocorticosteroids are an effective therapy choice in the initial treatment of most IBD cases, a retrospective population-based American study reported 28% and 22% steroid dependency in Crohn's disease and UC patients and 16% steroid resistance after one year of treatment ([@b61-btt-2-355]). In addition, several studies report a high frequency of steroid resistance of Caucasian IBD patients and high surgical interventions ([@b142-btt-2-355]; [@b169-btt-2-355]; [@b61-btt-2-355]).

Nuclear factor kappa B (NF-κB) and p38 mitogen-activated protein kinase pathways (MAPK) have been shown to be present in rheumatoid arthritis and inflammatory bowel disease lesions and are therefore interesting targets for pharmacological intervention ([@b134-btt-2-355]; [@b210-btt-2-355]; [@b186-btt-2-355]; [@b223-btt-2-355]). NF-κB constitutes a ubiquitously expressed family of inducible dimeric transcription factors that regulate the expression of many genes whose encoded products prominently affect immune functions and cell death decisions ([@b99-btt-2-355]). Target genes of NF-κB can be categorized as inhibitors of apoptosis, promoters of cell proliferation and inflammatory mediators ([@b98-btt-2-355]). Studies show that aminosalicylates and corticosteroids, used to treat IBD, inhibit cytokine-induced activation of NF-κB. Sulfasalazine blocks activity of the IKK complex in intestinal epithelial cells, and mesalamine has been reported to have similar effects ([@b224-btt-2-355]). Moreover, mesalamine can also inhibit phospohorylation of the p65 subunit of NF-κB, a post-translational modification that is essential for its transcriptional activity ([@b58-btt-2-355]). Corticosteroids have been shown to block NF-κB activation in a number of different mechanisms, including transcription upregulation of IκBα, an important endogenous inhibitor of NF-κB, and through competition for limiting pools of essential transcriptional co-activators, such as p300 ([@b5-btt-2-355]). In addition to these drugs that can directly inhibit NF-κB activation, antibodies against tumor necrosis factor-α can also limit NF-κB activity by neutralizing this cytokine, which is a potent activator of NF-κB. While all of these mechanisms have been studied in *in vitro* experiments, it is not established to what extent NF-κB inhibition is the precise molecular mechanism that underlies the beneficial effects of any of these drugs *in vivo*. In terms of MAPK pathways, currently there is a controversy whether there is a significant activation of MAPK pathways in experimental murine colitis or in human inflammatory bowel disease. So far the results to assess if MAPK inhibitors might be beneficial in inflammatory bowel disease have been inconsistent and several trials failed to demonstrate efficacy ([@b207-btt-2-355]; [@b86-btt-2-355], [@b87-btt-2-355]; [@b132-btt-2-355]).

In addition to NF-κB and p38 MAPK, the peroxisome proliferator activated receptor-γ (PPARγ) is a nuclear receptor controlling the expression of a large number of regulatory genes in lipid metabolism and insulin sensitisation, as well as in inflammation and cell proliferation ([@b52-btt-2-355]; [@b60-btt-2-355]). The role of this receptor in gut homeostasis has been described in numerous articles and it has been linked with such conditions as IBD, Crohn's disease, UC, colitis and ileitis ([@b198-btt-2-355]; [@b197-btt-2-355]; [@b104-btt-2-355]; [@b185-btt-2-355]). In the study by [@b165-btt-2-355], mice were gavaged with PPARγ agonists prior to colitis induction. Animals were treated with rosiglitazone and after 16 days impairment of colitis was observed. This positive outcome initiated further testing, this time in clinical trials. In the study by [@b119-btt-2-355], the efficacy of rosiglitazone was tested on 15 patients with mild to moderately active UC. Thirteen of 15 patients were receiving concomitant therapy with corticosteroids and/or immunomodulator medications. There was a decrease observed in disease with clinical and endoscopic remission (27% and 20%, respectively) or part response (27%) in eight patients. This study in IBD patients led to new clinical trials in IBD with these chemical compounds, and may lead to the development of safer PPAR-γ agonist with topical effects and targeting selectively the colon ([@b56-btt-2-355]).

Colon cancer
------------

Colorectal cancer is the most common cancer in Western countries and the second leading cause of cancer-related deaths. Colorectal cancer is the second leading cause of cancer-related deaths in the United States, accounting for nearly 60,000 deaths each year ([@b96-btt-2-355]). In addition, at least 100 million patients in the USA and Canada have recurrent long-term GI problems. According to the National Cancer Institute, cancer of the colon is the second leading cancer diagnosis among both women and men in United States. Sporadic lesions represent 75%--80% of all colorectal cancer, whereas 20%--25% are in younger individuals or in patients with a family history of cancer, suggesting a heritable susceptibility ([@b174-btt-2-355]). Although there have been recent advances in adjuvant therapy, there are no major breakthroughs in the treatment of colorectal cancers. Animal studies have provided important insights into the etiology of colon cancer, but there have been no major advances in the prevention of this disease. For instance, pancreatic cancer still contributes to high mortality rates since the average survival time after its detection is less than one year. The lack of treatment is due to no advances made in understanding the cause of this disease.

A recent *in vitro* study investigated a new drug for treatment of metastatic colorectal cancer, irinotecan (CPT-11) ([@b117-btt-2-355]). The cytotoxic effect of the new drug was evaluated alone and in combination with mitomycin C (MMC) and hyperthermia on three colorectal cancer cell lines: CACO-2, HT-29, and DHD/K12/TRb (PROb). It was found that the combination of CPT-11 and MMC had a large spectrum of cytotoxicity in *in vitro* models. This indicates that a clinical use of intraperitoneal chemohyperthermia with MMC and CPT-11 to treat colorectal peritoneal carcinomatosis of colorectal origin was designed. However, further *in vivo* studies need to confirm these findings.

*In vitro* and *in vivo* studies tested the effect of combined therapy with demethylating agent 5-aza-2'-deoxycytidine (DAC) and irinotecan (CPT-11) on the human colon cancer cell line HCT-15 ([@b93-btt-2-355]). It was postulated that DAC might increase the tumor sensitivity to chemotherapy through demethylation and restoration of gene expression. It was concluded that pretreatment with low-dose DAC may have the potential to be used as a "biosensitizer" of DNA-damaging agents such as CPT-11 when the apoptotic pathway is inactivated as a result of aberrant promoter methylation in the cancer.

There are some studies indicating that regular use of NSAIDs may be associated with decreased colorectal cancer risk ([@b156-btt-2-355], [@b155-btt-2-355]; [@b168-btt-2-355]; [@b24-btt-2-355]). However, the studies did not take into consideration whether the lowering of the cancer incidence was due to tumors of the proximal or distal colon. In a study by [@b131-btt-2-355], the impact of NSAIDs on the proximal and distal colon was evaluated. The study found statistically not significant association between either distal colon or rectal cancer and aspirin or nonaspirin NSAID use. Unfortunately, the use of NSAID drugs like aspirin, whether enteric- or nonenteric-coated, leads to side effects like GI bleeding ([@b100-btt-2-355]; [@b166-btt-2-355]; [@b6-btt-2-355]) and digestive complications ([@b112-btt-2-355]; [@b195-btt-2-355]). A comprehensive review on aspirin-related GI side-effects and the mechanism by which aspirin causes GI damage was published by [@b85-btt-2-355].

Although much has been learned about the incidence of colorectal cancer in patients who have IBD and its correlation with disease activity, duration, and anatomic location; almost no data are available regarding specific therapeutic considerations during adjuvant or palliative chemotherapy for these patients with respect to their underlying disease ([@b71-btt-2-355]). Today the adjuvant therapy for colorectal cancer consists primarily of combinations of 5-fluorouracil/leucovorin (5-FU/LV) (with infusional or bolus 5-FU) with oxaliplatin or oral capecitabine. In addition, bevacizumab, the angiogenesis inhibitor and cetuximab the epidermal growth factor receptor inhibitor are supplemented ([@b50-btt-2-355]). In depth results of Phase III trials of infusional 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX) as a new standard of care in the palliative and adjuvant treatment of colorectal cancer have been summarized in a review by [@b76-btt-2-355]. In addition to already mentioned pharmacologic treatments, the nonpharmacologic ones are being widely tested as well and reported to modestly alter sporadic adenoma recurrence rates in randomized trials. These include calcium ([@b83-btt-2-355]), folic acid ([@b115-btt-2-355]), and selenium ([@b73-btt-2-355]). [Table 1](#t1-btt-2-355){ref-type="table"} summarizes the above GI diseases and their treatment limitations.

Limitations
-----------

Dyspepsia, nausea, vomiting, diarrhea, and constipation are just few of many side effects increasingly seen in patients taking GI drugs ([@b118-btt-2-355]). Mucosal ulceration that can manifest as GI hemorrhage, stricture, and perforation are examples.

In one study, 1.4 million people aged 66 years and older were examined for upper GI hemorrhage in British Columbia and Ontario ([@b133-btt-2-355]). It was observed that patients treated with selective cyclooxygenase-2 (COX-2) inhibitors had increased upper GI hemorrhage. Although in a recent report by [@b111-btt-2-355] we find out that selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) are safer to the GIT than traditional NSAIDs, they may increase the incidence of serious cardiovascular adverse events (CVEs). In addition, coxib therapy is more expensive than combination therapy using a nonselective NSAID and a proton-pump inhibitor ([@b90-btt-2-355]). Another study clearly states that NSAIDs produce symptoms of dyspepsia and peptic ulcer disease in up to 50% and up to 20%, respectively, of individuals taking them ([@b158-btt-2-355]).

Nonsteroidal antiinflammatory drug toxicity in the upper GIT is the most common serious drug-induced toxicity reported to drug regulatory authorities. While differences exist between NSAIDs and aspirin, most studies have shown that advanced age, history of peptic ulcer disease, serious concomitant illnesses, and coprescription of NSAID/aspirin with anticoagulants and steroids are high risk factors. The use of potent antiulcer therapy, treatment of *H. pylori* infection and the development of COX-2 inhibitor will change the scenario of NSAID/aspirin-related GI toxicity in the next millennium ([@b203-btt-2-355]).

To sum up, many promising fields have already contributed to a better understanding of some of the underlying mechanisms of GI diseases. By means of pharmacogenetics, molecular genetics, introduction of immune-modulators and monoclonal antibodies and other techniques great advances have been made in the management of the above diseases. However, a curative safe therapy does not yet exist. Due to the presence of specific bacterial populations in the colon and an apparent transient, small reversal in the otherwise increasing pH gradient are factors which vastly limit and delay the already extensively explored research for initiating colon-specific drug release ([@b234-btt-2-355]).

The use of drugs is still *an essential part of the physician's armamentarium. However,* given the evolving potential side-effects information, physicians and patients should weigh the benefits and risks of these treatments. The drug use and drug coverage policies should be more restrictive; although limiting access to drugs and their potential benefits may protect the population from adverse drug effects as well as the need to routinely reassess patients' health.

Delivery of bacterial cells currently used for treating GI specific diseases
============================================================================

According to [@b55-btt-2-355], a probiotic is a "live microbial food ingredients that, when ingested in sufficient quantities, exerts health benefits on the consumer". Lactic acid bacteria (LAB) are the organisms most commonly used as probiotics ([@b179-btt-2-355]). Probiotics exert their benefits through several mechanisms; they prevent colonization, cellular adhesion and invasion by pathogenic organisms, they have direct antimicrobial activity and they modulate the host immune response. The strongest evidence for the clinical effectiveness of probiotics has been in their use for the prevention of symptoms of lactose intolerance, treatment of acute diarrhea, attenuation of antibiotic-associated GI side effects and the prevention and treatment of allergy manifestations.

An interesting study was performed by [@b66-btt-2-355] with probiotic strains and their adherence patterns in the gut and in mucosal immune stimulation. *Lactobacillus casei* interaction with the gut was observed using transmission electron microscopy (TEM). The study demonstrated that only antigenic particles interact with the immune cells and their fast clearance from the gut agrees with those described for the particulate antigens.

The above study proved that regular ingestion of probiotics does not interfere with the host gut microflora but does exert health benefits on the consumer. In another study with guinea pigs the intestinal motility changes were monitored by testing 8 bacterial strains belonging to *Bifidobacterium*, *Lactobacillus*, and *Streptococcus* genera within the probiotic preparation VSL\#3 ([@b222-btt-2-355]). The outcome revealed that the proximal colon relaxation activity showed by the probiotic bacteria could be one of the possible mechanisms of action by which probiotics exert their positive effects in regulating intestinal motility ([@b136-btt-2-355]).

Although, probiotic therapy modulates the composition of the intestinal flora and is believed to inhibit the inflammatory response, the metabolic activity of some intestinal microorganisms inhabiting the gut may lead to the production of harmful substances. These substances could be metabolically undesirable (eg, d-lactic acid for the newborn) or might lead to potentially carcinogenic substances such as *N*-nitroso compounds ([@b72-btt-2-355]). Therefore a thorough assessment of specific strains as well as doses seems to be essential.

The following section summarizes numerous studies which tested probiotic bacterial strains in treatment of various diseases.

Various GI diseases treated with biotherapeutics
================================================

Rotavirus diarrhea, acute diarrhea, antibiotic-associated diarrhea
------------------------------------------------------------------

There has been a great amount of research done in the field of probiotics and their effect on diarrhea. Rotavirus diarrhea is the major cause of infantile gastroenteritis worldwide and the infection is associated with approximately 600,000 deaths every year, predominantly in developing countries. A study by [@b30-btt-2-355] and [@b23-btt-2-355] focused on treatment of acute diarrhea using *Saccharomyces boulardii*. A randomized, double-blind, placebo controlled clinical trial was conducted by [@b178-btt-2-355] to screen *Lactobacillus casei* strain GG in the treatment of infants with acute watery diarrhea. A meta-analysis was performed by [@b89-btt-2-355] to validate the efficacy of probiotic use in acute diarrhea in children where a co-administration of probiotics with standard rehydration therapy reduced the duration of acute diarrhea by approximately one day. Another study on 55 infants aged 5--24 months, was performed by [@b177-btt-2-355] to explore the prevention of diarrhea in hospitalized infants using *Bifidobacterium lactis* (BB12) and *Streptococcus thermophilus. Lactobacillus GG* was used in prevention of nosocomial diarrhea in infants in the study by [@b205-btt-2-355] which concluded that a prophylactic use of *Lactobacillus GG* significantly reduced the risk of nosocomial diarrhea in infants, particularly nosocomial rotavirus gastroenteritis. *Lactobacillus reuteri* and *B. lactis* were compared in a double-blind, placebo-controlled, randomized trial by [@b226-btt-2-355] to screen for preventative properties of daycare illness with positive results suggesting that children supplemented with formulas with *L. reuteri* or *B. lactis* had fewer and shorter episodes of diarrhea, with no effect on respiratory illnesses. The effects of long-term consumption of a fermented infant formula (with *Bifidobacterium breve c50* and *Streptococcus thermophilus 065* was evaluated on acute diarrhea in healthy infants with the outcome that a fermented formula may reduce the severity of acute diarrhea among healthy young infants which may be linked to the bifidogenic effects of fermentation products and their interactions with the intestinal immune system ([@b209-btt-2-355]).

A randomized placebo-controlled double-blind study with 220 hospitalized children was conducted to assess the efficacy of *Lactobacillus GG* vs. breast-feeding in the prevention of rotavirus nosocomial infection concluding that breast feeding was more beneficial ([@b137-btt-2-355]). *Saccharomyces boulardii* and placebo were used in an antibiotic-associated diarrhea prevention randomized-controlled trial by [@b105-btt-2-355] with 269 children reaching positive evidence that *S. boulardii* effectively reduces the risk of antibiotic-associated diarrhea in children because only 8% had presence of diarrhea. A meta-study screening the efficacy of probiotics in prevention and treatment of diarrhea associated with the use of antibiotics was done using 9 randomized double-blind placebo-controlled trials with children with 4 yeast, 4 lactobacilli and 3 combination of bacteria by [@b47-btt-2-355] concluded that the evidence of probiotics beneficial role still needs to be proven by designing a larger scale study. Another randomized, placebo-controlled trial was conducted using the probiotic *Lactobacillus rhamnosus* strain *GG* (LGG) to see if the addition of LGG to standard therapy prolonged remission in children with Crohn's disease by [@b16-btt-2-355] with 75 children which resulted in median time to relapse of 9.8 months for LGG group and 11 months for placebo group. In this study the differences were not statistically significant but no benefit of probiotics was apparent ([@b16-btt-2-355]). A study using *L. acidophilus* and *B. infantis* was conducted on 367 preterm infants in treatment of necrotizing enterocolitis by [@b122-btt-2-355] and resulted in death of 7 vs 20 a significantly lower in the study when compared with the control group. [@b148-btt-2-355] studied *Lactobacillus salivarius UCC4331* and *Bifidobacterium infantis 35624* in 77 adult IBS patients to compare the response of symptoms and cytokine ratios after ingestion of probiotic preparations resulting in *B. infantis* reducing pain, bloating and suggesting an immune-modulating role for this organism.

Gastric ulcers caused by *Helicobacter pylori*
----------------------------------------------

In a double-blind, randomized, controlled clinical trial, 326 *H. pylori*-infected school children from a low social economic area of Santiago, Chile were treated with both live and heat-killed strains of *Lactobacillus johnsonii*, *Lactobacillus paracasei* or vehicle once daily for 4 weeks. A C13-urea breath test demonstrated a significant fall in *H. pylori* colonization in children receiving live *L. johnsonii*, but not the other groups. Once again, this study implies a probiotic species specificity for the therapeutic effect ([@b44-btt-2-355]). [@b194-btt-2-355] have screened the impact of *Lactobacillus*- and *Bifidobacterim*-containing yogurt on *H. pylori* in 138 patients. The suppression rate was improved in eradication rate by quadruple therapy of residual *H. pylori* after failed triple therapy. Another study focused on *H. pylori*-infected children by administration of a probiotic, *Lactobacillus acidophilus* and comparing its efficacy with a synbiotic, *Saccharomyces boulardii* plus inulin (SbI) ([@b74-btt-2-355]). The study concluded that *S. boulardii* may serve as an agent that fights *H. pylori* in colonized individuals. In the presence of clarithomycin-resistant *H. pylori*, eradication is significantly attenuated. An interesting randomized study was run on 85 *H. pylori* patients undergoing eradication with triple therapy using the following probiotics: *Lactobacillus casei* subspecies *rhamnosus*, *Saccharomyces boulardii*, *Lactobacillus acidophilus* plus *Bifidobacterium lactis* or placebo ([@b42-btt-2-355]). As a result, all the groups given probiotics performed better than placebo group but failed to be superior to antibiotic therapy. [@b214-btt-2-355] demonstrated that *Lactobacillus gasseri* inhibited both the *in vitro* growth of clarithomycin-resistant *H. pylori* and the release of IL-8 from epithelial cells. In addition, in an *in vivo* mouse model, *H. pylori* colonization was significantly decreased by *Lactobacillus gasseri*. Another inhibitory effect was demonstrated by [@b32-btt-2-355] in a study with *Lactobacillus acidophilus* on *H. pylori* growth. In addition to studies screening the efficacy of probiotic strains in treatment of H. pylori infection, another study confirmed a positive impact that *Lactobacillus GG* has on GI side-effects caused by *H. pylori* antibiotic therapy ([@b4-btt-2-355]). The above studies support the complementary effect of probiotics in the management of *H. pylori* infection.

The role of *H. pylori* in the management of nonulcer dyspepsia produced numerous *H. pylori* eradication regimens, but despite many studies no perfect therapy has been identified so far. The American College of Gastroenterology has published a set of guidelines for the treatment and prevention of NSAID-induced ulcers ([@b114-btt-2-355]). This contains a well-motivated, practical approach to the problem of NSAID ulceration; emphasizes the "risk profile" approach to selection of patients for prophylaxis; and presents compelling arguments against the routine use of H~2~-receptor antagonists for NSAID prophylaxis. The role of *H. pylori* is also addressed. Screening for *H. pylori* infection in NSAID users is not currently recommended, but patients with past or present ulceration who need NSAID therapy should also receive eradication therapy ([@b124-btt-2-355]). Lau and colleagues () questioned the conventional wisdom that surgery is indicated for peptic ulcer rebleeding.

Inflammatory bowel disease
--------------------------

Inflammatory bowel disease (IBD) is a chronic disease of the digestive tract, and usually refers to two related conditions, namely UC and Crohn's disease, characterized by chronic and spontaneously relapsing inflammation. Although the etiology of IBD is still insufficient, there is increasing experimental evidence to support a role for luminal bacteria in the initiation and progression of these intestinal conditions; probably related to an imbalance in the intestinal microflora, relative predominance of aggressive bacteria and insufficient amount of protective species ([@b64-btt-2-355]; [@b192-btt-2-355]). The current hypothesis in the pathogenesis of the chronic idiopathic IBD, Crohn's disease, and UC, suggests that these are caused by an overly aggressive cell-mediated immune response to luminal commensal bacteria in genetically susceptible hosts ([@b184-btt-2-355]; [@b193-btt-2-355]). In addition, IBDs are multifactorial processes and clinical and animal studies indicate that emotional stress may contribute to the onset and progress of these diseases. On the other hand, enhanced free radical production in mucosal cells has been also implicated in the pathogenesis of IBD ([@b40-btt-2-355]). This disease was described for the first time in 1952 ([@b43-btt-2-355]) and today, it has been estimated that at least 3.5 million Americans visit their physicians each year for IBD which accounts for 25% of all patients seen in gastroenterologists' practice, with 15,000--30,000 new cases being diagnosed each year ([@b59-btt-2-355]). Crohn's disease is most common in the developed countries of Europe, Scandinavia, and the US and generally is thought to be more common in whites ([@b182-btt-2-355]).

In the systematic review by [@b91-btt-2-355] it was estimated that £45.6 million was spent annually in the UK for IBD care, translating into approximately £90 annually in costs per patient. On the other hand, the annual mean direct costs of caring for IBS patients in Canada were estimated to be US\$260 ([@b11-btt-2-355]).

A primary goal in treating CD is to control GIT inflammation. Currently, the treatment of this disease is based on its degree of inflammation and consists of dietary adjustments, surgery and various medications including antiinflammatory drugs, steroids, immunosuppressants, antibiotics, antitumor necrosis factor (anti-TNF) drugs, antidiarrheals and other symptom suppressing drugs. However, an ideal treatment is yet to be found ([@b22-btt-2-355]; [@b77-btt-2-355]). As in other inflammatory processes, IBD is characterized by an upregulation in the synthesis and release of different pro-inflammatory cytokines, including reactive oxygen and nitrogen metabolites, eicosanoids, platelet-activating factor, and cytokines ([@b200-btt-2-355]). All of these mediators contribute to the pathogenic cascade that initiates and perpetuates the inflammatory response of the gut. As a consequence, and until its etiology has been completely elucidated, the best strategy to effectively down-regulate intestinal inflammation is to interfere with multiple stages of the inflammatory cascade, preferably with a single drug treatment ([@b68-btt-2-355]).

Serological markers such as anti-*Saccharomyces cerevisiae* antibodies (ASCA) and atypical perinuclear antineutrophilic cytoplasmic antibody (atypical pANCA) have proven useful in the diagnosis and differentiation of Crohn's disease and UC ([@b95-btt-2-355]).

Biologic and other novel therapies targeted to specific pathogenic processes offer the potential for improved treatment outcomes in patients with CD and alteration of the course of the disease ([@b181-btt-2-355]). A possible therapeutic approach in IBD therapy is the administration to these patients of probiotic microorganisms, defined as viable nutritional agents conferring benefits to the health of the human host ([@b157-btt-2-355]).

This complex interplay of genetic, microbial and environmental factors culminates in a sustained activation of the mucosal immune and nonimmune response, probably facilitated by defects in the intestinal epithelial barrier and mucosal immune system, resulting in active inflammation and tissue destruction. Under normal situations, the intestinal mucosa is in a state of 'controlled' inflammation regulated by a delicate balance of pro-inflammatory (TNF-α^,^ interferon \[IFN\]-γ, interleukin \[IL\]-1, IL-6, IL-12) and anti-inflammatory cytokines (IL-4, IL-10, IL-11). The mucosal immune system is the central effector of intestinal inflammation and injury, with cytokines playing a central role in modulating inflammation ([@b3-btt-2-355]). For inflammatory bowel diseases (IBD) the most important cytokines identified are IL-1, IL-2, IL-6, IL-8, IFN^-^γ, and TNF-α ([@b217-btt-2-355]). Cytokines may, therefore, be a logical target for IBD therapy using specific cytokine inhibitors.

At present, the biological therapies that are being used in clinical practice or investigated for the treatment of IBD are predominantly proteins, usually delivered intravenously or subcutaneously. The therapies used include: 1. TNF-α inhibitors: infliximab, CDP 571, etanercept, onercept, CNI-1493, and thalidomide. 2. Inhibitors of lymphocyte trafficking: natalizumab, LPD-02 and ICAM-1. 3. Inhibitors of Th1 polarization: monoclonal antibodies for IL-12, IFN-γ and anti-IFN-γ. 4. Immunoregulatory cytokines: IL-10 and IL-11. 5. Inhibitors of NF-κB. 6. Growth factors: epidermal growth factor (EGF) and keratinocyte growth factor (KGF) ([@b108-btt-2-355]). Therefore, targeted molecules can be specifically eliminated in their expression directly on the transcriptional level. Interesting therapeutic trials are expected against ICAM-1 and pro-inflammatory signaling molecules (ie, NF-κB). The future development of immune therapies in IBD therefore holds great promises for better treatment modalities of IBD but will also open important new insights into a further understanding of inflammation pathophysiology ([@b188-btt-2-355]).

Current treatment of IBD is rather effective though it is only working in symptomatic fashion. Most recombinant "biologicals" have not been an overwhelming success. Infliximab has shown clinically relevant efficacy and is used in patients not responding to the standards. Alternatives such as modulating the bacterial-epithelial interaction, tightening of the mucosal barrier and maybe even immunostimulation should be studied since most recent finding on etiology and pathophysiology point to a disturbed barrier with consequent abnormal bacterial epithelial interaction as the main problem in the IBD syndrome ([@b187-btt-2-355]).

There is currently a growing appreciation for the role of the enteric flora in health and disease. In the past years overwhelming evidence has accumulated for the role of commensal gut bacteria in the IBD, Crohn\'s disease, and UC. Both entities are mainly located in areas with high bacterial concentrations ([@b14-btt-2-355]).

In the last decade there were five main clinical trials that examined various probiotics, namely species of *Lactobacillus*, in the treatment of IBD ([@b81-btt-2-355]; [@b146-btt-2-355]; [@b149-btt-2-355]; [@b144-btt-2-355]; [@b190-btt-2-355]). In the past years, many reviews have been written about IBS as well as the role of microflora in IBS ([@b130-btt-2-355]; [@b65-btt-2-355]). In a randomized controlled clinical trial, [@b101-btt-2-355] examined the effects of a probiotic formulation containing eight different probiotic species, VSL\#3 supplementing 450 billion lyophilized bacteria/day (VSL Pharmaceuticals Inc.), on GI transit and symptoms of patients with diarrhea predominantly IBS. After 10 weeks of treatment, there was no significant difference in mean GI transit measurements, bowel function scores or satisfactory global symptom relief between the two treatment groups. However, VSL\#3 appears to be a promising agent in IBS as it significantly reduced the abdominal bloating ([@b101-btt-2-355]).

The mechanism of action of probiotics in IBS remains still poorly understood due to changes and complexity in fermentation products. Another study screened for lactobacilli, bifidobacteria, *Streptococcus thermophilus*, enterococci, coliforms, Bacteroides and *Clostridium perfringens* changes in the fecal composition of 10 patients with diarrhea-predominant IBS after administration of VSL\#3 probitocs with positive results yielding no significant alterations in indigenous flora ([@b17-btt-2-355]). In a similar open-label study, [@b10-btt-2-355] made use of the following hypothesis: "characteristics of the luminal milieu, the relationship, the balance between luminal prokaryotic cells and mucosal eukaryotic cells and the consequent immunological and humoral local and systemic responses take part in the pathophysiology of several diseases and, consequently bacteriotherapy can play a relevant role in the treatment and prevention of IBS and more in general, of the intestinal functional disorders". He demonstrated that VSL\#3 probiotic induced changes in the composition of the colonic microflora together with improvement in colonic dysmotility and in visceral perception. On the other hand, in a double-blind, placebo-controlled, crossover, four-week trial of Lactobacillus plantarum 299V in 12 previously untreated patients the probiotic did not alter colonic fermentation or improve symptoms in comparison with placebo ([@b190-btt-2-355]). An interesting study designed to confirm the efficacy of the probiotic bacteria *B. infantis* in a large-scale, multicenter, clinical trial of women with IBS as well as to determine the optimal dosage of probiotic for administration in a freeze-dried, encapsulated formulation was performed in UK ([@b229-btt-2-355]). A dose of 1 × 10(8) cfu was the most stable, convenient and amenable to widespread use in IBS and that *B. infantis* relieved many of the IBS symptoms. Further studies evaluated the effect of probiotics *Bacillus subtilis*, *Streptococcus faecium* in a form of Medilac DS on GI symptoms and intestinal gas volume changes in forty patients with IBS ([@b102-btt-2-355]). After 4-week treatment, it was found that both probiotics are safe and useful agents in patients with IBS. The efficacy of *Lactobacillus GG* was screened in the randomized, double-blinded, placebo-controlled study with 50 children for 6 weeks suffering from IBS ([@b9-btt-2-355]). Although *Lactobacillus GG* turned out not to be superior to placebo in the treatment of abdominal pain in children with IBS it still may be promising in relieving such symptoms as perceived abdominal distention. The above studies present promising options in treatment of IBS as we gain more insightful information about the disease itself as well as variety of available probiotics with beneficial properties. However, what needs to be emphasized is that these summarized results support the concept of specific probiotic strains being more effective that others across varied disease states.

Collagenous colitis
-------------------

Collagenous colitis is a chronic inflammatory bowel disease that affects the colon ([@b230-btt-2-355]). It is also considered to be a cause of chronic diarrhea. Collagenous and lymphocytic colitis have been recognized as chronic intestinal inflammatory disorders causing watery diarrhea, which have been recognized in the past three to two decades, respectively. In a double-blind placebo-controlled study supervised by [@b231-btt-2-355] the effectiveness of probiotic treatment, namely: *Lactobacillus acidophilus* and *Bifidobacterium animalis* subsp*. lactis* has been screened in patients with collagenous colitis. The study concluded that probiotic treatment may potentially influence the disease course of collagenous colitis. In another trial, the therapeutic clinical benefit was found of probiotic *E. coli* strain *Nissle* 1917 (EcN) in patients with collagenous colitis ([@b212-btt-2-355]).

Intestinal diseases caused by *Escherichia coli*
------------------------------------------------

There are five types of *E. coli*, enterotoxigenic, enteropathogenic, enteroadherent, enteroinvasive, and enterohemorrhagic *E. coli*, which are responsible for as much as 25% of all diarrheal diseases in developing countries. They tend to be transmitted via contaminated foods, particularly weaning foods, and water ([@b145-btt-2-355]). In an *in vitro* study, the effect of probiotic *Lactobacillus casei GG* (LGG) was tested to find out that it has the effect of reducing the rate of *E. coli* C25 (*E. coli* C25) translocation. The study was performed using an *in vitro* cell-culture model with human colonic carcinoma (Caco-2) enterocytes. It was concluded that the probiotic bacterium *LGG* inhibits bacterial translocation of *E. coli* C25 in a dose-dependent manner in an *in vitro* cell-culture model ([@b138-btt-2-355]). In the study by [@b2-btt-2-355] with 24 children a commercial capsule or powder containing *S. boulardii* was administered once a day for 5 days to screen for the number of *E. coli* colonies in the colon. It was found that *S. boulardii* may be effective in reducing the number of *E. coli* colonies in stool which may lead to preventative treatment of urinary tract infections.

Colorectal cancer
-----------------

Colorectal cancer, whether sporadic or hereditary, is caused by a defined set of molecular events ([@b206-btt-2-355]). Germline mutations in tumor-suppressor adenomatous polyposis coli (APC) genes and DNA mismatch repair (MMR) genes lead to the recognized familial adenomatous polyposis (FAP)-related colorectal cancer and the hereditary non-polyposis colorectal cancer (HNPCC), respectively ([@b181-btt-2-355]). Bacterial flora keeps the normal colon mucosa in a continuous state of low-grade inflammation, stimulating release of various pro-inflammatory cytokines by the immune cells ([@b172-btt-2-355]).

Anastomotic leakage of colonic and rectal anastomoses is a major complication after an intraperitoneal large-bowel anastomosis in patients with colorectal malignancy and after large intestine surgery. It is associated with a 6%--22% mortality rate. Many factors influence the healing of colon anastomoses. Flavonoids have been recognized for centuries as physiologically active constituents that are used to treat human diseases ([@b92-btt-2-355]).

Anal sphincter function is increasingly preserved following rectal excision for cancer and provides a better quality of life for patients than does a permanent colostomy. However, anastomotic complications may cause considerable morbidity and mortality ([@b53-btt-2-355]).

The use of probiotics in prevention and cancer treatment has been undergoing a recent evaluation in a number of studies. Although we should not expect miraculous outcomes in cancer treatment following probiotics administration, their immunomodulatory properties have been tested and need to be brought to publics' attention. In the study by [@b139-btt-2-355] *Lactobacillus acidophilus* (Delvo Pro LA-1), *Lactobacillus rhamnosus* (GG), *Bifidobacterium animalis* (CSCC1941), and *Streptococcus thermophilus* (DD145) strains were examined for their influence on 1,2-dimethylhydrazine (DMH)-induced intestinal tumors in 100 male Sprague-Dawley rats when added as freeze-dried bacteria. This study concluded that the strain of *L. acidophilus* supplied as freeze-dried bacteria in the diet was protective because it significantly inhibited tumors within the rat colon. There is a substantial amount of studies done by Perdignon dealing with anti-inflammatory properties of probiotic bacteria. For instance, the probiotic bacterium *Lactobacillus casei* was screened for its influence on the expression of receptors involved in the innate immune response in colorectal cancer BALB/c model mice ([@b67-btt-2-355]). Further, a complex nature of kefir was studied in BALB/c mice. Kefir is fermented milk produced by the action of lactic acid bacteria, yeasts and acetic acid bacteria, trapped in a complex matrix of polysaccharides and proteins. In addition, it is an excellent source of proteins and calcium ([@b219-btt-2-355]). A conclusion was drawn that since different components of kefir have an *in vivo* role as oral biotherapeutic substances capable of stimulating immune cells of the innate immune system they are able to downregulate the Th2 immune phenotype or to promote cell-mediated immune responses against tumors and also against intracellular pathogenic infections ([@b220-btt-2-355]). Another kefir-related study was done by [@b219-btt-2-355] which was the first *in vivo* study to determine the immunomodulating capacity of kefir on the intestinal mucosal immune response in mice of viable or heat-inactivated bacteria at different doses. The adjuvant immunomodulatory effect of kefir was tested in rats, young and old ([@b211-btt-2-355]). An enhanced *in vitro* antibody secretion by cultured lymphocytes isolated from the Peyer's patches and the intestinal lamina propria were found only in young rats indicating that the administration of kefir to young rats has a beneficial effect on intestinal mucosal immune response against cholera toxin.

Probiotics are useful in a variety of diarrheal diseases and may be useful in inflammatory and allergic disorders. [Table 2](#t2-btt-2-355){ref-type="table"} summarizes the above described diseases and lists biotherapeutics used in their treatment, their dose, mode of delivery and potential site of action. In [Table 3](#t3-btt-2-355){ref-type="table"}, a proposed mechanism of action is described along with marketed probiotic-containing products. It is important to note that the effects are strain- and dose-specific and therefore more clinical studies are needed to be designed screening each strain and disorder. Other problems that probiotic production may encounter include: oxygen stress due to agitation during pH control, oxygen and pressure stresses during centrifugation or filtration, membrane damages during freeze-drying due to freezing itself and due to the drying step. In addition, such situations like production of inhibitory compounds by starter cultures, heating--pasteurization, freezing, food additives (salt, spices, flavors) and drying could further alter viability of probiotic species. However, probiotics appear to be safe, as it was shown in treatment with infants.

Microencapsulated live oral biotherapeutics, their potential and limitations
============================================================================

It was [@b121-btt-2-355] who invented alginate-poly-[l]{.smallcaps}-lysine-alginate (APA) microcapsule in 1980 and ever since microencapsulation has been proven to be an effective strategy for cell implantation and cell-based gene therapy for the treatment of diabetes, metabolic or neurologic, disorders, and cancer ([@b176-btt-2-355]; [@b180-btt-2-355]; [@b8-btt-2-355]; [@b125-btt-2-355]). As it was noted before, to obtain an efficient colon targeting biotherapeutics, the delivered materials need to be protected from the GI environment and remain functionally unaltered on arrival to the site.

As mentioned earlier, in order for any microorganism be able to stimulate the gut immune system, for instance probiotic bacteria, they should be resistant to the enzymes in the oral cavity (amylases and lysozyme), to the low acidic pH in the stomach and to the presence of bile acids, pancreatic juice and mucus in the small intestine. These properties are important for survival in the small and large bowel. Micro-organisms must also be able to persist within the GIT and to adhere to gut epithelial tissue. Another important consideration expressed in the probiotic definition is the one concerned with the viability of the micro-organisms ([@b66-btt-2-355]). Although [@b154-btt-2-355] received interesting results while working on treatment for acute diarrhea suggesting that in some cases nonviable bacteria are able to produce effects similar to those obtained with viable bacteria, these findings need to be further explored and proven effective in treatment of other diseases.

The principle of microencapsulation, its design and potentials in live biotherapeutics delivery
===============================================================================================

Cell microencapsulation consists of enclosing cells, such as primary cells, cell lines and genetically engineered cells to secrete therapeutic product in a semipermeable membrane ([@b29-btt-2-355]). It is a process by which a liquid or solid active ingredient (encapsulated material) is packaged within an inert material (encapsulant) to protect the microencapsulated materials from the surrounding environment, or conversely to protect the environment from the active ingredient. Artificial cells refer to manmade microscopic structures that possess some functional properties of biological cells. The membrane allows bidirectional diffusion of nutrients, oxygen, metabolites, and waste but prevents high molecular weight substances, such as antibodies and immunocytes, from entering the microcapsule, which provides an immune protection for the cells. Microcapsule membrane can be made of natural (alginate, arabinoglycan, chitosan, agarose, poly-[l]{.smallcaps}-lysine, xylan and collagen) or synthetic polymers (polyaminoacids, polyacrylates, chondroitin sulfate, cyclodextrin) ([@b239-btt-2-355]). Other plant-derived polysaccharides, such as amylase, inulin, pectin and guar gum are known to remain unaffected in the presence of GI enzymes which enable the way for the formulation of the colon targeted delivery systems ([@b38-btt-2-355]). APA microencapsulation is one of the most well-studied encapsulation technologies, including entrapment of cells in alginate gel beads, formation of alginate-poly-[l]{.smallcaps}-lysine membrane, and liquefying of the alginate gel core to leave the cell floating in the center of the microcapsule ([@b126-btt-2-355]). Studies show that APA encapsulation yields intact capsules that preserve their integrity and are able to retain live bacterial cells ([@b213-btt-2-355]) ([Figure 2](#f2-btt-2-355){ref-type="fig"}). Moreover, genetically engineered bacteria have been encapsulated and used in oral therapy ([@b160-btt-2-355], [@b161-btt-2-355]).

Cell microencapsulation is one of the promising strategies for the *in vitro* production of proteins or *in vivo* delivery of therapeutic products ([@b227-btt-2-355]). In addition to *in vitro* culture, implantation of microencapsulated cells represents a promising strategy for the controlled, localized, and long-term *in vivo* delivery of therapeutic products to the hosts ([@b152-btt-2-355]). Bioencapsulation has provided a range of promising therapeutic treatments for diabetes ([@b202-btt-2-355]), hemophilia ([@b88-btt-2-355]), cancer ([@b232-btt-2-355]), and renal failure ([@b160-btt-2-355]). Although it might not serve yet as a replacement technology to existing treatment modalities, it surely can serve as an alternative method should present ones fail. Today, with its potential and greatly increasing interest, the field of microencapsulation should shortly receive an extensive scrutinization which will shortly allow its application as a complementary treatment method to already well established methods.

Methods of live biotherapeutics cell delivery
=============================================

Microencapsulation technology raises great potential in delivery of biotherpeutics live cells in medicine and biotechnology. In order to maintain microencapsulated cultures properties, it needs to be enclosed in a system that provides optimal conditions for their viability targeted delivery and functionality. The microcapsules preparation include physical methods like: pan coating, air-suspension coating, centrifugal extrusion, vibrational nozzle, spray-drying and chemical methods like: interfacial polymerization, *in situ* polymerization, matrix polymerization.

Oral artificial bacterial cell therapy is a therapy which is based on oral delivery of live bacterial cells which are enclosed in artificial polymeric membrane. Clinical trials suggest potential beneficial effects of probiotic therapy for preventing and treating antibiotic-associated diarrhea, acute diarrhea including rotavirus-induced diarrhea, traveler's diarrhea, and diarrhea-predominant IBS. The most extensively studied probiotics for diarrhea are *Lactobacillus*, *Bifidobacterium* and *Saccharomyces*, with potential mechanisms of therapeutic action based on the protection of intestinal epithelial cell and barrier function, prevention of enterotoxin binding to intestinal epithelial cells, and regulation of intestinal microbial environment ([@b233-btt-2-355]). The release patterns include: pressure, shear stress, melting, dissolving, solvents, enzymes, chemical reactions, hydrolysis, slow disintegration, and pH.

The mathematical models have been built for animal cell growth, tumor cell growth ([@b163-btt-2-355]), such as Gompertzian growth, logistic growth, or exponential growth law ([@b171-btt-2-355]). Various systems are listed in [Table 4](#t4-btt-2-355){ref-type="table"}. Microencapsulation is a suitable technique to deliver various biotheraputics to a wide spectrum of cells and tissues enhancing the potential applicability of this strategy. Numerous applications include pharmaceuticals, dyes, agrochemicals, flavors and fragrances and other commercial possibilities.

Conclusions and future perspectives
===================================

At the start of the 21st century, research is poised at the interphase where artificial cells now range from macrodimensions, to microndimensions, to nano-dimensions, and to molecular dimensions. Cell encapsulation represents an alternative non-viral approach for the long term delivery of therapeutic products. A comprehensive review covering delivery of live bacterial cells has been published by [@b162-btt-2-355].

Another review outlining the safety of current probiotic compounds has been published ([@b15-btt-2-355]). Cases of infection due to lactobacilli and bifidobacteria are extremely rare, and are estimated to occur at a rate of approximately 0.05%--0.4% of all cases of infective endocarditis and bacteremia ([@b15-btt-2-355]). No increase in bacteremia caused by *Lactobacillus* species was seen in Finland over the period from 1999 to 2000, despite an increased consumption of *Lactobacillus rhamnosus* GG ([@b94-btt-2-355]). Nevertheless, case reports have identified fungemia in two immunosuppressed patients ([@b173-btt-2-355]) and exacerbation of diarrhea in two patients with UC ([@b21-btt-2-355]) who consumed *Saccharomyces boulardi*. Few other case reports have been published of infection caused after use of probiotics, like development of sepsis in premature neonates with short gut syndrome and chronic intestinal inflammation after consumption of *Lactobacillus* GG ([@b107-btt-2-355]). Also *Lactobacillus rhamnosus* infection cases have been reported in elderly patients, a 74-year-old woman ([@b167-btt-2-355]) and a 67-year-old man ([@b129-btt-2-355]) who developed a liver abscess and tooth infection, respectively. The advantages of oral administration may result in the popularization of this mode of therapy once more data is produced about the incorporation of biologically active agents such as bacteria in therapeutics or advanced food systems and once it has been shown such option is safe and efficient.

So far, the current data is promising and raises hopes in medicine and biotechnology. However, the amount of clinical trials is still insufficient to conclude the overall safety of probiotic strains and other biotherapeutics use in therapy. Much work is still needed to exploit these benefits and to increase our understanding of their mechanisms, for instance improvement of microcapsule membrane designs, methods for improved cell harvest, the mass production of artificial cell microcapsules and the overall cost effective storage and clinical efficacy. Nevertheless, the already available data suggests that only time and additional high quality outcome studies are needed to yield more promising and convincing results. Ultimately, the efficacy, long-term safety and cost effectiveness of these therapies will prove their worth.
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![Schematic representation of molecular toll-like receptors (TLRs) of the human gastrointestinal (GI) tract which act as sensors and are the first responders in the major pathway by which the immune system detects infection or damaged tissue. Their biological function makes them attractive targets for designing various biotherapeutic molecules for such disorders as inflammation, infections, autoimmunity, allergies and cancer.](btt-2-355f1){#f1-btt-2-355}

![(**a**) Photomicrograph of freshly prepared empty APA microcapsules.\
(Magnification 6.3x). (**b**) Photomicrograph of freshly prepared APA microcapsules loaded with L. *acidophilus*. (Magnification: 2.5x). (**c**) Photomicrograph of APA microcapsules loaded with L. acidophilus cells after 76 hours of incubation in MRS broth and 150 rpm in-vitro shaking at 37 ºC (Magnification: 6.3x)180.](btt-2-355f2){#f2-btt-2-355}
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Various gastrointestinal diseases and their treatment limitations

  Disease                      Proposed treatment             Potential adverse symptoms/problems                                           References
  ---------------------------- ------------------------------ ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Collagenous colitis          Prednisolone                   Accumulation of lymphocytes in the colonic epithelium and connective tissue   [@b57-btt-2-355]; [@b116-btt-2-355]
                               Boswellia serrata                                                                                            
                                                              Thickening of the subepithelial collagen table                                
  Diarrhea                     Prednisolone                   Frequent watery, loose bowel movements                                        [@b199-btt-2-355]; [@b31-btt-2-355]; [@b63-btt-2-355]
                               Omeprazole                                                                                                   
                               Asprin                         Damage to the mucosal lining                                                  
                               Bisphosphonates                An inhibition of absorption                                                   
  Microscopic colitis          Bismuth subsalicylates         Profuse watery diarrhea                                                       [@b1-btt-2-355]; [@b24-btt-2-355]; [@b26-btt-2-355]
                               Budesonide                     Higher incidence of immune diseases                                           
                               Prednisolone                                                                                                 
                               Boswellia serrata                                                                                            
                               Cholestyramine                                                                                               
                               5-aminosalicylic acid                                                                                        
  Gastritis                    Omeprazole                     Antibiotic resistance                                                         [@b204-btt-2-355]; [@b25-btt-2-355]; [@b141-btt-2-355]; [@b236-btt-2-355]
                               Aspirin                        Gastric ulcers                                                                
                               Mistoprostol                   Gastrointestinal bleeding                                                     
                               Tetracycline                   Recurrent abdominal pain                                                      
                               Metronidazole                  Increased gastric cancer risk                                                 
  Inflammatory bowel disease   Sulfasalazine                  Leukopenia                                                                    [@b142-btt-2-355];
                               Mesalazine                     Mononucleosis-like syndrome                                                   [@b169-btt-2-355]; [@b61-btt-2-355]; [@b150-btt-2-355];
                               Azathioprine                   Nephrotoxicity                                                                
                               6-mercaptopurine               Steroid resistance which leads to surgical interventions                      [@b208-btt-2-355]; [@b159-btt-2-355]
                               Methotrexate                                                                                                 
                               Glucocorticosteroids                                                                                         
                               Infliximab                                                                                                   
  Colon cancer                 Irinotecan (CPT-11)            Toxicity                                                                      [@b100-btt-2-355]; [@b166-btt-2-355];
                               Mitomycin C (MMC)              Gastrointestinal bleeding                                                     [@b6-btt-2-355]; [@b195-btt-2-355]; [@b76-btt-2-355]; [@b50-btt-2-355]; [@b93-btt-2-355]; [@b111-btt-2-355]; [@b117-btt-2-355]; [@b131-btt-2-355]
                               5-aza-2'-deoxycytidine (DAC)   Digestive complications                                                       
                               irinotecan (CPT-11)            Temporary effect on bone marrow                                               
                               NSAID                                                                                                        
                               5-fluorouracil/ leucovorin     Hair loss                                                                     
                               (5-FU/LV)                      Anemia                                                                        
                               Oxaliplatin Capecitabine       Overall fatigue                                                               
                                                              May increase cardiovascular adverse events                                    
                                                              Lowered resistance to infections                                              
                                                              No data about specificity of treatments                                       

###### 

Various pathological conditions treated with viable microorganisms (bacteria or yeasts) -- probiotics

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                                             Biotherapeutics used                                                                                                                                                                                                                                   Live bacterial cell optimal dose   Mode of delivery   Potential site of action                        References
  --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------- ------------------ ----------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------
  Rotavirus diarrhea                                  *Lactobacillus GG*                                                                                                                                                                                                                                     \~10^10^/d                         Capsules           Small and large intestines                      [@b177-btt-2-355]; [@b205-btt-2-355]; [@b47-btt-2-355]; [@b89-btt-2-355]; [@b137-btt-2-355]; [@b178-btt-2-355]; [@b209-btt-2-355]; [@b78-btt-2-355]

  *Lactobacillus reuteri*                             \~10^9^/d                                                                                                                                                                                                                                              Foods                                                                                                 

  *Lactobacillus acidophilus*                         \~10^10^/d                                                                                                                                                                                                                                                                                                                                                   

  *Lactobacillus bulgaricus*                          \~10^8^/ml                                                                                                                                                                                                                                                                                                                                                   

  *Bifidobacterium bifidum*                           \~10^10^/d                                                                                                                                                                                                                                                                                                                                                   

  *Streptococcus*                                     500 mg/d                                                                                                                                                                                                                                                                                                                                                     

  *thermophilus*                                      500 mg/d                                                                                                                                                                                                                                                                                                                                                     

  *Saccharomyces boulardi*                            \~10^10^/d                                                                                                                                                                                                                                                                                                                                                   

  *Lactobacillus casei*                               \~10^10^/d                                                                                                                                                                                                                                                                                                                                                   

  *Bifidobacterum bulgaris*                                                                                                                                                                                                                                                                                                                                                                                        

  Antibiotic associated diarrhea                      *Saccharomyces boulardi*                                                                                                                                                                                                                               500 mg/d                           Capsules           Small and large intestines                      [@b47-btt-2-355]; [@b105-btt-2-355]

  *Lactobacillus GG*                                  \~10^10^/d                                                                                                                                                                                                                                             Foods                                                                                                 

  Radiation induced diarrhea                          *VSL\#3 (Lactobacillus casei*, *Lactobacillus plantarum*, *Lactobacillus acidophilus*, *Lactobacillusdelbruekii* ssp. *bulgaricus*, *Bifidobacterium longum*, *Bifidobacterium breve*, *Bifidobacterium infantis* and *Streptococ cus thermophilus*)   4.5 × 10^9^/2 capsules             Capsules           Small and large intestines                      [@b54-btt-2-355]

  *Helicobacter pylori* colonization/gastric ulcers   *Lactobacillus johnsonni*                                                                                                                                                                                                                              \~10^10^/d                         Capsules           Stomach, duodenum, small and large intestines   [@b44-btt-2-355]; [@b32-btt-2-355]; [@b214-btt-2-355]; [@b74-btt-2-355]; [@b194-btt-2-355]

  *Saccharomyces boulardi*                            500 mg/d                                                                                                                                                                                                                                                                                                                                                     

  *Lactobacillus acidophilus*                         \~10^10^/d                                                                                                                                                                                                                                                                                                                                                   

  *Lactobacillus gasseri*                             \~10^8^/d                                                                                                                                                                                                                                                                                                                                                    

  Inflammatory bowel disease                          *Escherichia coli Nissle*\                                                                                                                                                                                                                             500 mg/d                           Capsules           Small intestines                                [@b16-btt-2-355]
                                                      *Saccharomyces boulardi*                                                                                                                                                                                                                                                                                                                                     

  (IBD)                                               *VSL\#3*                                                                                                                                                                                                                                                                                                                                                     

                                                      *Lactobacillus GG*                                                                                                                                                                                                                                     \~10^10^/d                                                                                            

  Ulcerative Colitis                                  *Escherichia coli Nissle*                                                                                                                                                                                                                                                                 Capsules           Small and large intestines                      [@b81-btt-2-355]; [@b113-btt-2-355]; [@b170-btt-2-355]

  Irritable bowel syndrome                            *Lactobacillus plantarii*                                                                                                                                                                                                                              \~10^10^/d                         Capsules           Small and large intestines                      [@b81-btt-2-355]; [@b149-btt-2-355]; [@b146-btt-2-355]; [@b17-btt-2-355]; [@b114-btt-2-355]; [@b10-btt-2-355]; [@b190-btt-2-355]; [@b148-btt-2-355]

  *Bifidobacterium infantis*                          \~10^10^/d                                                                                                                                                                                                                                                                                                                                                   

  Collagenous colitis                                 *Lactobacillus acidophilus*                                                                                                                                                                                                                            \~10^10^/d                         Capsules           Large intestines                                [@b231-btt-2-355]

  *Bifidobacterium animalis* subsp*. Lactis*          \~10^10^/d                                                                                                                                                                                                                                             Injections                                                                                            

  Colorectal cancer                                   *Lactobacillus acidophilus*                                                                                                                                                                                                                                                               Capsules           Large intestines                                [@b139-btt-2-355]; [@b211-btt-2-355]; [@b219-btt-2-355], [@b220-btt-2-355]; [@b67-btt-2-355]

  *Lactobacillus rhamnosus*                           Milk                                                                                                                                                                                                                                                                                                                                                         

  *Bifidobacterium animalis*                          Kefir                                                                                                                                                                                                                                                                                                                                                        

  *Streptococcus thermophilus*                                                                                                                                                                                                                                                                                                                                                                                     

  Lactobacillus casei                                                                                                                                                                                                                                                                                                                                                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Biotherapeutics, gastroenteric pathogens and their proposed mechanism of action and current marketed biotherapeutics products

  Marketed probiotic products                                Probiotic content                                                                                Disease causing microorganisms and their proposed mec                           
  ---------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Culturelle                                                 *Lactobacillus GG*, *Lactobacillus rhamnosis*                                                    *Clostridium difficile*                                                         -- Produce antimicrobial substances with activity against the homologous strain
  *Campylobacter jejuni*                                                                                                                                                                                                                      
  VSL (VSL\#3)                                               *Lactobacillus casei*,                                                                           *Helicobacter pylori*                                                           
                                                             *Lactobacillus plantarum*,                                                                       Rotavirus -- leading etiologic agents of nosocomial infections among children   -- Produce microbicidal substances with effect against gastric and intestinal pathogens and other microbes
                                                             *Lactobacillus acidophilus*,                                                                                                                                                     
                                                             *Lactobacillus delbruekii ssp. bulgaricus*, *Bifidobacterium longum*, *Bifidobacterium breve*,                                                                                   
  Atopic disease -- eczema, asthma and rhinoconjunctivitis                                                                                                                                                                                    
  -- Compete for cell surface and mucin binding sites                                                                                                                                                                                         
                                                             *Bifidobacterium infantis and*                                                                   Salmonella                                                                      
                                                             *Streptococcus thermophilus*                                                                     Campylobacter                                                                   -- Inhibit or decrease translocation of bacteria from the gut to the liver
  *Escherichia coli*                                                                                                                                                                                                                          
  Florastar, Ultra Levure                                    *Saccharomyces boulardii*                                                                                                                                                        
                                                                                                                                                              *Staphylococcus aureus*                                                         -- Bind mutagens by intestinal bacteria
  Flora Q                                                    *Lactobacillus acidophilus*,                                                                     Shigella spp.                                                                   -- Reduce enzymes beta-glucoronidase and beta-glucosidase
                                                             *Lactobacillus paracasei*,                                                                       *Yersinia enterocolitica*                                                       
                                                             *Bifidobacterium*,                                                                                                                                                               -- Deconjugate bile acids
                                                             *S. thermophilus*                                                                                                                                                                -- Enhance immune system of the host
  Yakult (Japan)                                             *Lactobacillus GG*                                                                                                                                                               -- Stimulate intestinal mucin secretion

###### 

Microcapsule membrane systems features

  Delivery vehicles                                                                                                                                                                      Features                                                                                        Reference
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alginate-poly-[l]{.smallcaps} -lysine-alginate                                                                                                                                         -- Most studied system for encapsulation of living cells                                        [@b126-btt-2-355]; [@b160-btt-2-355], [@b161-btt-2-355]; [@b103-btt-2-355]; [@b175-btt-2-355]; [@b216-btt-2-355]; [@b201-btt-2-355]; [@b51-btt-2-355]; [@b213-btt-2-355]
  -- Formed by immersion of the calcium alginate beads in an aqueous solution of poly--L--lysine                                                                                                                                                                                         
  -- Allows for proliferation of encapsulated cells and prolongs the survival of xeno--graphs implanted both intraperitoneally and subcutaneously                                                                                                                                        
  -- Used for encapsulated cells in industry, medicine, and agriculture, production of ethanol by yeast, lactic acid by lactic acid bacteria, monoclonal antibodies by hybridoma cells                                                                                                   
  -- Tested in gene, cell and enzyme therapies                                                                                                                                                                                                                                           
  -- Simple and safe encapsulation procedure at physiological conditions                                                                                                                                                                                                                 
  -- Long--term *in vivo* applications cause graft failures                                                                                                                                                                                                                              
  Alginate-agarose microcapsules                                                                                                                                                         -- Cell survival dependent on cell lines                                                        [@b152-btt-2-355]
  -- Viability maintained for more than 70 days with no aggregates formation                                                                                                                                                                                                             
  -- Mechanical stability compromised                                                                                                                                                                                                                                                    
  Alginate-chitosan (AC) microcapsules                                                                                                                                                   -- Low cost                                                                                     [@b7-btt-2-355]; [@b69-btt-2-355]; [@b191-btt-2-355]; [@b151-btt-2-355]
  -- Sturdier membrane than APA                                                                                                                                                                                                                                                          
  -- Improved mechanical stability and reduced cell leakage                                                                                                                                                                                                                              
  -- Suitable for mammalian and microbial cell growth and functions                                                                                                                                                                                                                      
  Genipin cross-linked AC microcapsules                                                                                                                                                  -- Covalent link created by naturally occurring genipin                                         [@b34-btt-2-355], [@b33-btt-2-355], [@b35-btt-2-355]
  -- Enhanced membrane strength and durability                                                                                                                                                                                                                                           
  Alginate-PMCG-alginate capsules                                                                                                                                                        -- Improved membrane strength                                                                   ([@b153-btt-2-355])
  -- Easily adjusted capsule size and wall thickness                                                                                                                                                                                                                                     
  -- Oligomeric PMCG may be cytotoxic                                                                                                                                                                                                                                                    
  Alginate-cellulose sulfate-poly- (methylene-co-guanidine) (A-CS-PMCG) system                                                                                                           -- Improved mechanical strength                                                                 [@b18-btt-2-355]; [@b18-btt-2-355]; [@b147-btt-2-355]; [@b19-btt-2-355]; [@b20-btt-2-355]
  -- Easy control over membrane thickness                                                                                                                                                                                                                                                
  -- Oligomeric PMCG may be immunogenic                                                                                                                                                                                                                                                  
  -- Yet to test long--term stability                                                                                                                                                                                                                                                    
  Polyvinlyamine hydrochloride-based microcapsules                                                                                                                                       -- Mechanically stable                                                                          [@b75-btt-2-355]
  -- Permeability can be controlled over a wide range                                                                                                                                                                                                                                    
  PHEMA-MMA system                                                                                                                                                                       -- Water insoluble                                                                              [@b189-btt-2-355]; [@b215-btt-2-355]; [@b106-btt-2-355]
  -- Better stability and durability                                                                                                                                                                                                                                                     
  -- Limited cell survival and mass transfer in some applications                                                                                                                                                                                                                        
  Chitosan core-poly (MAA-HEMA-MMA) shell                                                                                                                                                -- Prepared in physiological conditions                                                         [@b241-btt-2-355]
  -- Controllable mechanical strength and permeability                                                                                                                                                                                                                                   
  -- Supported hepatocytes growth                                                                                                                                                                                                                                                        
  -- Maintained cell functions                                                                                                                                                                                                                                                           
  Collagen core complexed with terpolymer HEMA-MAA-MMA-shell                                                                                                                             -- Improved mechanical strength and chemical stabilizing                                        [@b37-btt-2-355]; [@b237-btt-2-355]; [@b164-btt-2-355]
  -- Enhanced cell functions                                                                                                                                                                                                                                                             
  Sodium cellulose sulfate and poly (dimethyldiallylammonium chloride) system (NaCD-PDMDAAC)                                                                                             -- MWCO less than 2 KD if prepared by standard method addition of pore forming agent (starch)   [@b48-btt-2-355], [@b49-btt-2-355]; [@b140-btt-2-355]; [@b238-btt-2-355]; [@b236-btt-2-355]
  -- Increased cutoff to 70 KD for protons                                                                                                                                                                                                                                               
  -- Allowed secretion and release of therapeutics by the encapsulated cells.                                                                                                                                                                                                            
